Global Immune Checkpoint Inhibitors Market Size By Type (CTLA-4 inhibitors, PD-1 inhibitors), By Application (Lung Cancer, Bladder Cancer), By Geographic Scope And Forecast

Immune Checkpoint Inhibitors Market Size And Forecast

Immune Checkpoint Inhibitors Market size was valued at USD 39.33 Billion in 2022 and is projected to reach USD 129.68 Billion by 2030, growing at a CAGR of 16.08% from 2023 to 2030.

The Global Immune Checkpoint Inhibitors Market is witnessing significant growth during the forecasted period due to various driving factors including growing demand for Immune Checkpoint Inhibitors for cancer treatment, growing prevalence of cancers across the world, and increasing awareness about Immune Checkpoint Inhibitors, and rest of the others. The market is expected to grow steadily throughout the forecast period due to government initiatives towards cancers, regulatory approvals, and growing healthcare spending in developed as well as developing economies around the world. The Global Immune Checkpoint Inhibitors Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Immune Checkpoint Inhibitors Market Definition

Immune Checkpoint Inhibitor is a kind of medication that inhibits the production of checkpoint proteins by immune system cells such as T cells and cancer cells. These checkpoints prevent too-aggressive immune responses and, in some cases, prevent T cells from destroying cancer cells. T lymphocytes can attack cancer cells more effectively when these checkpoints are disabled. PD-1/PD-L1 and CTLA-4/B7-1/B7-2 are two checkpoint proteins discovered on T cells or cancer cells. Some immune checkpoint inhibitors are utilized in cancer treatment.

PD-1 and PD-L1 inhibitors are anticancer medications combined with checkpoint inhibitors that suppress the action of PD-1 and PDL1-resistant checkpoint proteins found on the surface of cells. Immune checkpoint inhibitors are becoming a first-line therapy for a variety of cancers. PD-1 and PD-L1 inhibitors act by preventing programmed death ligand 1 (PD-L1) from binding to its receptor, programmed cell death protein 1. (PD-1). The interaction of these cell surface proteins is important in immune system suppression and happens after infection to minimize the death of surrounding host cells and to prevent autoimmune illness.

Global Immune Checkpoint Inhibitors Market Overview

Immunotherapeutic therapy strategies are being developed as one of the primary cancer treatment methods. PD-1/PD-L1 inhibitors take a tailored strategy, which reduces toxicity while increasing efficacy. Because of therapeutic success, the market for PD-1/PD-L1 inhibitors is growing. PD-1/PD-L1 inhibitors have shown effectiveness in the treatment of a variety of malignancies. PD-1/PD-L1 inhibitors are being researched for use in the treatment of different cancers. The global market is expanding because of the growth in cancer occurrence across geographies and greater knowledge of immune checkpoint inhibitors. The number of patients suffering from cancer is rising over time worldwide.

According to the Canadian Cancer Society, approximately 28.2% of deaths in Canada are caused due to cancer. Canadian Cancer Researchers had forecasted that there will be an addition of 229,200 new cancer cases in Canada; out of which 84,600 cancer patients will die. Moreover, the cancer mortality rate has been decreasing to 37% in men and 22% in women till 2021, due to the different types of treatments. The number of cancer patients is also rising in Mexico accounting for increased costs to the country per capita every year. According to the Pan American Health Organization, there were 190,667 cancer cases in Mexico, in 2018; out of which 83,476 cancer patients died. The number of cancer cases will rise in Mexico and reach 1,262,861 in the next decade, according to the American Society of Clinical Oncology.

Approximately, a quarter of men and 20% of women out of the total cancer patients in Germany, died of cancer. It is forecasted that around 51% of men and 43% of women will develop cancer across Germany by 2030, according to the National Library of Medicine. According to the World Cancer Research Fund International, the cancer rate for men and women in Germany was 313.1 per 100,000 in 2018. In France, the UK, Italy, and Spain, it was 344.1, 319.2, 290.6, and 272.3 per 100,000 respectively. Also, Europe had the highest rate of lung cancer in 2018, according to the World Cancer Research Fund International. Death rates due to cancer are also increasing in the European continent as different types of cancers such as lung cancer, bladder cancer, colorectal cancer, and the rest the others, are among the European population.

Cancer is becoming seen as a serious hazard to human existence due to its high fatality rate. Furthermore, many forms of cancer are affecting individuals all over the world. As a result, more money is being invested in research to create medications for a variety of disorders, such as immune system regulatory proteins. Furthermore, technical developments in cancer screening processes, growing healthcare spending, increased government cancer-fighting measures, and higher public awareness are expected to propel the market ahead. However, the high expense of product research and development raises the cost of the completed product and associated revisions, thus slowing market growth.

Global Immune Checkpoint Inhibitors Market Segmentation Analysis

The Global Immune Checkpoint Inhibitors Market is segmented on the basis of Type, Application, And Geography.

Immune Checkpoint Inhibitors Market, By Type

• CTLA-4 Inhibitor
• PD-1 Inhibitor
• PD-L1 Inhibitor
• Others

Based on Type, the market is segmented into CTLA-4 Inhibitor, PD-1 Inhibitor, PD-L1 Inhibitor, and Others. PD-1 Inhibitor accounted for the largest market share in 2021 and is projected to grow at a significant CAGR during the forecast period. PD-1 inhibitors are a class of immune checkpoint inhibitors used as first-line therapy for a variety of cancers. Despite the promising therapeutic outcomes, the substantial immune-related side effects hampered the clinical deployment of PD-1 monoclonal antibodies. The dominance of the segment can be attributed to the increased volume of research activities, approvals, and the rise in prescriptions of these drugs such as nivolumab and pembrolizumab.

Immune Checkpoint Inhibitors Market, By Application

• Lung Cancer
• Bladder Cancer
• Melanoma
• Hodgkin Lymphoma
• Colorectal Cancer
• Others

Based on Application, the market is segmented into Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, Colorectal Cancer, and Others. Lung Cancer accounted for the largest market share in 2021 and is projected to grow at the highest CAGR during the forecast period. It is the result of an upsurge in pharmacological approvals for the treatment of various solid tumors during the previous four years. The market has also seen extensive research for the treatment of urogenital cancer, as well as many approvals for various technical improvements in the treatment of many tumors, which has contributed to the segment’s growth. However, the Colorectal Cancer segment is expected to grow with a significant CAGR during the forecasted period.

Immune Checkpoint Inhibitors Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

On the basis of Regional Analysis, the Global Immune Checkpoint Inhibitors Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America accounted for the largest market share and is projected to grow at a significant CAGR during the forecast period. One of the key factors for the rapid growth of the North America Immune Checkpoint Inhibitors Market is the sale of authorized therapies and the rising occurrence of blood-related cancers. Furthermore, the rising number of patient support programs offered by vendors is propelling the market in this area forward. However, the Asia-Pacific market is expected to grow with the highest CAGR during the forecasted period.

Key Players

The “Global Immune Checkpoint Inhibitors Market” study report will provide valuable insight with an emphasis on the global market including some of the major players such as AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Sanofi, Merck KGaA, BeiGene Ltd, Novartis, and Pfizer. This section provides a company overview, ranking analysis, company regional and industry footprint, and ACE Matrix.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

Key Developments

• In April 2022, Novartis announced that the European Medicines Agency (EMA) has approved the immune checkpoint inhibitor tislelizumab for adults with locally advanced or metastatic, squamous or non-squamous non-small cell lung cancer (NSCLC) as first-line treatment in combination with chemotherapy, locally advanced or metastatic NSCLC as monotherapy after prior chemotherapy, and unresectable, recurrent, locally advanced or metastatic esophageal cancer.
• In March 2022, Bristol Myers Squibb announced that Opdualag (nivolumab and relatlimab-rmbw), a new, first-in-class fixed-dose combination of nivolumab and relatlimab administered as a single intravenous infusion, has been approved by the United States Food and Drug Administration (FDA) for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.
• In August 2021, Pfizer announced a USD 2.26 billion acquisition of Trillium Therapeutics, located in Toronto and Cambridge, Massachusetts. Trillium is working on creating a new class of checkpoint inhibitors to treat cancer.

Ace Matrix Analysis

The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.

Market Attractiveness

The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Immune Checkpoint Inhibitors Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.

Porter’s Five Forces

The image provided would further help to get information about Porter’s five forces framework providing a blueprint for